Navidea Biopharma enrolls first patient in phase II Alzheimer’s trial of NAV4694

Wednesday, September 19, 2012 12:31 PM

Navidea Biopharmaceuticals, a Dublin, Ohio-based biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has commenced enrollment at two sites participating in its phase II, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

The open-label, multiple-center, non-randomized single dose, PET imaging study is designed to compare images from subjects with probable AD with similarly aged and young healthy volunteers. The two trial sites are currently enrolling subjects are Molecular NeuroImaging in New Haven, Conn., which dosed the first patient in the study, and the Alzheimer's Disease Center at Quincy Medical Center in Quincy, Mass.

"NAV4694 appears to exhibit the strengths of 11C PIB, but given that the ligand is labeled with 18F, it offers flexibility and is more practical to use,” said Danna Jennings, clinical research director, Molecular NeuroImaging. “The data at this point in the development suggest that NAV4694 shows favorable sensitivity, specificity and decreased white-matter uptake that may enable earlier Alzheimer's disease identification, better monitoring of disease progression, and easier scan interpretation."

Frederick Cope, senior vice president of pharmaceutical research and clinical development, Navidea, said, "Our ultimate goal is to provide an improved diagnostic tool with outstanding performance characteristics for physicians to aid in the diagnosis of AD, a disease expected to impact as many as 16 million Americans by 2050."

In addition to safety and efficacy objectives, the study also will measure the correlation between neuro-psychiatric test results with the amount of β-amyloid determined by the NAV4694 imaging.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs